• Tetratherix launches new precision medicine franchise leveraging Tetramatrix platform
• Exclusive R&D agreement with Superpower Health Inc to deliver nasal sprays for longevity and metabolic compounds
• Tetratherix expects 2 FDA approvals in bone regeneration franchise in mid-CY26

Tetratherix Limited (ASX:TTX) is pleased to announce a new precision medicine franchise leveraging its Tetramatrix platform polymer. This further endorses the versatility of the Tetramatrix platform and complements the company's existing bone regeneration, tissue spacing and tissue healing franchises. The precision medicine franchise will be immediately revenue generating via an exclusive research & development (R&D) agreement with the US consumer health group Superpower Health Inc (Superpower). Under the agreement, Superpower will pay TTX an exclusive licence payment of US$3 million per year for up to 10 years. Additionally, Superpower will purchase Tetramatrix platform polymer (branded as STEPP) for nasal delivery of longevity and metabolic compounds such as GLP-1, peptides and hormones in the US market.STEPP has been under stealth development by Tetratherix for over 5 years in collaboration with research institutions. It acts as a carrier vehicle for nasal delivery, forming a sticky cushion to anchor compounds in place and protect them from degradation. This allows for controlled release and improved bioavailability of delicate compounds like GLP-1s and peptides.Tetratherix confirms that all milestones across its existing franchises remain on track, with 2 FDA approvals expected in the bone regeneration franchise in mid-CY26. The precision medicine franchise is entirely additive and the revenue generated under the Superpower agreement is expected to strengthen Tetratherix's cash position without diverting resources from the core programs.The partnership with Superpower, a leader in the precision health movement, allows Tetratherix to gather real-world evidence on health outcomes and preferences, with the goal of becoming the delivery mechanism for a new era of preventative healthcare.

Tetratherix expects to receive 2 FDA approvals in the bone regeneration franchise in mid-CY26.

The precision medicine franchise is expected to generate immediate revenue through the exclusive R&D agreement with Superpower Health Inc, providing an additional revenue stream without diverting resources from Tetratherix's core programs.